1. Home
  2. GPRK vs STTK Comparison

GPRK vs STTK Comparison

Compare GPRK & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Geopark Ltd

GPRK

Geopark Ltd

HOLD

Current Price

$9.73

Market Cap

629.3M

Sector

Energy

ML Signal

HOLD

Logo Shattuck Labs Inc.

STTK

Shattuck Labs Inc.

HOLD

Current Price

$5.36

Market Cap

538.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GPRK
STTK
Founded
2002
2016
Country
Colombia
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
629.3M
538.3M
IPO Year
2009
2020

Fundamental Metrics

Financial Performance
Metric
GPRK
STTK
Price
$9.73
$5.36
Analyst Decision
Hold
Buy
Analyst Count
1
7
Target Price
$8.50
$10.00
AVG Volume (30 Days)
653.4K
1.0M
Earning Date
05-06-2026
05-01-2026
Dividend Yield
1.26%
N/A
EPS Growth
N/A
53.02
EPS
N/A
N/A
Revenue
N/A
$1,000,000.00
Revenue This Year
$39.45
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$12.70
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.75
$0.71
52 Week High
$11.87
$8.33

Technical Indicators

Market Signals
Indicator
GPRK
STTK
Relative Strength Index (RSI) 42.35 51.54
Support Level $9.48 $3.22
Resistance Level $10.26 $6.81
Average True Range (ATR) 0.50 0.54
MACD -0.17 0.14
Stochastic Oscillator 15.08 93.98

Price Performance

Historical Comparison
GPRK
STTK

About GPRK Geopark Ltd

GeoPark Ltd is an independent energy company. Its diversified portfolio of assets consist of Llanos 34 Block in Colombia, CPO-5 Block, Llanos 86, Llanos 87, Llanos 104, Llanos 123, and Llanos 124 Blocks in the Llanos Basin. Its segments include Colombia, Argentina, Brazil and Ecuador, with the majority of the revenue derived from Colombia. It derives revenue from Sale of crude oil, Sale of purchased crude oil, and Sale of gas.

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

Share on Social Networks: